109 related articles for article (PubMed ID: 23383600)
41. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
42. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
43. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
44. How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients.
Shami PJ
J Natl Compr Canc Netw; 2012 Jan; 10(1):112-8; quiz 119. PubMed ID: 22223871
[TBL] [Abstract][Full Text] [Related]
45. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
Hwang WL; Chen TC; Lin HY; Chang MC; Hsiao PC; Bai LY; Kuo CY; Chen YC; Liu TC; Gau JP; Wang PN; Hwang WS; Kuo MC; Liu CY; Liu YC; Ma MC; Su NW; Wang CC; Wu YY; Yao M; Yeh SP; Cheng HW; Lee YM; Ku FC; Tang JL
Int J Hematol; 2022 May; 115(5):704-712. PubMed ID: 35212915
[TBL] [Abstract][Full Text] [Related]
46. [Chronic myeloid leukemia presenting with marked eosinophilia].
Haseyama Y; Takeda Y; Kumano K
Rinsho Ketsueki; 2018; 59(12):2594-2599. PubMed ID: 30626795
[TBL] [Abstract][Full Text] [Related]
47. Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.
Kelly K; Swords R; Mahalingam D; Giles FJ
Leuk Lymphoma; 2010 Aug; 51(8):1399-413. PubMed ID: 20528247
[TBL] [Abstract][Full Text] [Related]
48. Monitoring molecular response in chronic myeloid leukemia.
Cortes J; Quintás-Cardama A; Kantarjian HM
Cancer; 2011 Mar; 117(6):1113-22. PubMed ID: 20960522
[TBL] [Abstract][Full Text] [Related]
49. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia.
Quintás-Cardama A; Kantarjian H; Cortés JE
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10 Suppl 1():S14-9. PubMed ID: 20529803
[TBL] [Abstract][Full Text] [Related]
50. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Noens L; Hensen M; Kucmin-Bemelmans I; Lofgren C; Gilloteau I; Vrijens B
Haematologica; 2014 Mar; 99(3):437-47. PubMed ID: 24598855
[TBL] [Abstract][Full Text] [Related]
51. Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia.
Faber E; Kuba A; Zapletalová J; Divoká M; Rožmanová Š; Rohoň P; Holzerová M; Jarošová M; Indrák K;
J Interferon Cytokine Res; 2012 May; 32(5):230-4. PubMed ID: 22191465
[TBL] [Abstract][Full Text] [Related]
52. Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting.
Agarwal MB
Indian J Med Paediatr Oncol; 2014 Jan; 35(1):10-6. PubMed ID: 25006277
[TBL] [Abstract][Full Text] [Related]
53. Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
Smirnikhina SA; Chelysheva EY; Lavrov AV; Kochergin-Nikitsky KS; Mozgovoy IV; Adilgereeva EP; Shukhov OA; Petrova AN; Bykova AV; Abdullaev AO; Turkina AG; Kutsev SI
Leuk Lymphoma; 2018 Oct; 59(10):2512-2515. PubMed ID: 29424604
[No Abstract] [Full Text] [Related]
54. [Relationship between BCR-ABL
Hu CY; Yu D; Zhan B; Han YH; Zhang HX; Li ZY; Zeng LY; Yan ZL; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1281-1287. PubMed ID: 30295239
[TBL] [Abstract][Full Text] [Related]
55. Practical monitoring of chronic myelogenous leukemia: when to change treatment.
Saglio G; Fava C
J Natl Compr Canc Netw; 2012 Jan; 10(1):121-9. PubMed ID: 22223872
[TBL] [Abstract][Full Text] [Related]
56. Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.
Haguet H; Graux C; Mullier F; Dogné JM; Douxfils J
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429056
[TBL] [Abstract][Full Text] [Related]
57. Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.
Shah NP
J Clin Oncol; 2018 Jan; 36(3):220-224. PubMed ID: 29206554
[TBL] [Abstract][Full Text] [Related]
58. Are chronic myeloid leukemia patients ready to stop long-term treatment?
Breccia M; Efficace F
Leuk Lymphoma; 2017 Dec; 58(12):2976-2978. PubMed ID: 28535695
[No Abstract] [Full Text] [Related]
59. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.
Broglie L; Hijiya N; Helenowski IB; Dilley K; Schneiderman J; Tse W; Duerst R; Kletzel M; Morgan E; Chaudhury S
Leuk Lymphoma; 2016; 57(4):949-52. PubMed ID: 26694579
[No Abstract] [Full Text] [Related]
60. Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
Garrisi VM; Sgherza N; Breccia M; Iacobazzi A; De Tullio G; Nardelli G; Negri A; Divella R; Daniele A; Micelli G; Tufaro A; Cascavilla N; Savino E; Abbate I; Guarini A
Leuk Lymphoma; 2018 Apr; 59(4):1016-1018. PubMed ID: 28695760
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
